Severe Immune-Related Adverse Events in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma Are Associated with PDCD1 Polymorphism

Single nucleotide polymorphisms (SNPs) reportedly influence the effect of nivolumab in metastatic renal cell carcinoma (mRCC). This study aimed to evaluate the relationship between the clinical outcomes of patients with mRCC and SNPs in programmed cell death protein 1 (PD-1) protein-coding gene (PDCD1) and explore any potential correlation with patient prognosis and incidence of immune-related adverse events (irAEs). In total, 106 patients with mRCC, who were treated with nivolumab alone (n = 59) or nivolumab and ipilimumab (n = 47), were enrolled in the study. Three SNPs in the PDCD1 gene, namely PD-1.3, PD-1.5, and PD-1.6, were assessed. Patients harboring the PD-1.6 G allele experienced more severe (odds ratio, 3.390; 95% confidence interval 1.517–7.756; p = 0.003) and multiple (OR, 2.778; 95% CI, 1.020–6.993 p = 0.031) irAEs than those harboring the AA genotype. Thus, the existence of the PDCD1 PD-1.6 polymorphism (G allele) was associated with the occurrence of severe and multiple irAEs in patients with mRCC. Further evaluation of PDCD1 polymorphisms might help identify patients experiencing irAE by nivolumab treatment.

[1]  C. Porta,et al.  Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. , 2021, The New England journal of medicine.

[2]  J. Aerts,et al.  Germline Variation in PDCD1 Is Associated with Overall Survival in Patients with Metastatic Melanoma Treated with Anti-PD-1 Monotherapy , 2021, Cancers.

[3]  H. Cordell,et al.  A PDCD1 Role in the Genetic Predisposition to NAFLD-HCC? , 2021, Cancers.

[4]  L. Karabon,et al.  Immune Checkpoint Molecules—Inherited Variations as Markers for Cancer Risk , 2021, Frontiers in Immunology.

[5]  L. Pickering,et al.  Individualizing Systemic Therapies in First Line Treatment and beyond for Advanced Renal Cell Carcinoma , 2020, Cancers.

[6]  R. Zdrojowy,et al.  SNP-SNP Interaction in Genes Encoding PD-1/PD-L1 Axis as a Potential Risk Factor for Clear Cell Renal Cell Carcinoma , 2020, Cancers.

[7]  H. Miyake,et al.  A multicenter retrospective study of nivolumab monotherapy in previously treated metastatic renal cell carcinoma patients: interim analysis of Japanese real-world data , 2020, International Journal of Clinical Oncology.

[8]  M. Merl,et al.  The impact of corticosteroid use during anti-PD1 treatment , 2020, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[9]  C. Porta,et al.  Correlation Between Immune-related Adverse Event (IRAE) Occurrence and Clinical Outcome in Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Nivolumab: IRAENE Trial, an Italian Multi-institutional Retrospective Study. , 2020, Clinical genitourinary cancer.

[10]  T. Habuchi,et al.  Efficacy and safety of nivolumab for renal cell carcinoma in patients over 75 years old from multiple Japanese institutes , 2020, International Journal of Clinical Oncology.

[11]  A. Vecchione,et al.  Reduced PD-1 expression on circulating follicular and conventional FOXP3+ Treg cells in children with new onset type 1 diabetes and autoantibody-positive at-risk children , 2020 .

[12]  M. Miyazato,et al.  A case report of nivolumab-induced myasthenia gravis and myositis in a metastatic renal cell carcinoma patient , 2019, Urology case reports.

[13]  T. Habuchi,et al.  Efficacy of anti-PD-1 antibody nivolumab in Japanese patients with metastatic renal cell carcinoma: A retrospective multicenter analysis. , 2019, Molecular and clinical oncology.

[14]  Kazuhiko Yoshida,et al.  Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab. , 2019, Urologic oncology.

[15]  P. Catalano,et al.  irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial , 2019, Clinical Cancer Research.

[16]  S. Sleijfer,et al.  Association between single-nucleotide polymorphisms and adverse events in nivolumab-treated non-small cell lung cancer patients , 2018, British Journal of Cancer.

[17]  Bohuslav Melichar,et al.  Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal‐Cell Carcinoma , 2018, The New England journal of medicine.

[18]  Arash Salmaninejad,et al.  PD-1 and cancer: molecular mechanisms and polymorphisms , 2018, Immunogenetics.

[19]  A. Sharpe,et al.  The diverse functions of the PD1 inhibitory pathway , 2017, Nature Reviews Immunology.

[20]  M. Fukuoka,et al.  Myasthenia gravis induced by nivolumab in patients with non-small-cell lung cancer: a case report and literature review. , 2017, Immunotherapy.

[21]  Shinya Yamamoto,et al.  Biomarkers to predict prognosis and response to checkpoint inhibitors , 2017, International Journal of Clinical Oncology.

[22]  Young Hak Kim,et al.  Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients , 2017, Scientific Reports.

[23]  Zhengwen Liu,et al.  Immune checkpoint proteins PD-1 and TIM-3 are both highly expressed in liver tissues and correlate with their gene polymorphisms in patients with HBV-related hepatocellular carcinoma , 2016, Medicine.

[24]  A. Ravaud,et al.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.

[25]  J. Terasaki,et al.  Low programmed cell death‐1 (PD‐1) expression in peripheral CD4+ T cells in Japanese patients with autoimmune type 1 diabetes , 2015, Clinical and experimental immunology.

[26]  Qianqian Zhu,et al.  microRNA-4717 differentially interacts with its polymorphic target in the PD1 3′ untranslated region: A mechanism for regulating PD-1 expression and function in HBV-associated liver diseases , 2015, Oncotarget.

[27]  Sai Lou,et al.  Association of polymorphisms of programmed cell death-1 gene with chronic hepatitis B virus infection. , 2010, Human immunology.

[28]  B. Guillonneau,et al.  Renal cell carcinoma in young and old patients--is there a difference? , 2008, The Journal of urology.

[29]  R. Yamada,et al.  Ethnic differences in allele frequency of autoimmune-disease-associated SNPs , 2005, Journal of Human Genetics.

[30]  R. Jonsson,et al.  A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans , 2002, Nature Genetics.

[31]  D. Bonaduce,et al.  Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue. , 2018, Current medicinal chemistry.

[32]  R. Herbst,et al.  Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer. , 2016, JAMA oncology.

[33]  Fengchun Zhang,et al.  The associations between PD-1, CTLA-4 gene polymorphisms and susceptibility to ankylosing spondylitis: a meta-analysis and systemic review , 2015, Rheumatology International.

[34]  O. Karadag,et al.  PDCD1 polymorphisms are not associated with Takayasu's arteritis in Turkey. , 2012, Clinical and experimental rheumatology.